A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study

A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study

Amantadine has begun to be used as a possible alternative in COVID-19 therapy to mitigate its effects. There is anecdotal evidence that patients with Parkinson's disease (PD) treated with amantadine and who test positive for COVID-19 often do not develop clinical manifestations of COVID-19.Obje...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova
Formaat:	Artikel
Taal:	Russian
Gepubliceerd in:	IMA-PRESS LLC 2022-12-01
Reeks:	Неврология, нейропсихиатрия, психосоматика
Onderwerpen:	parkinson's disease covid-19 new coronavirus infection amantadine sulfate levodopa α-synuclein pneumonia
Online toegang:	https://nnp.ima-press.net/nnp/article/view/1919

Gelijkaardige items

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
door: Aryun Kim, et al.
Gepubliceerd in: (2018-05-01)

Possibilities of using amantadines in the setting of the novel coronavirus infection in patients with Parkinson's disease
door: E. A. Katunina, et al.
Gepubliceerd in: (2021-12-01)

The comparative analysis of antiparkinsonian activity of glycine combined with amantadine in conditions of changing neurosynaptic transmission.
door: V. I. Mamchur, et al.
Gepubliceerd in: (2017-10-01)

Amantadine, new look at the well-known medicine
door: Andrzej Stańczak, et al.
Gepubliceerd in: (2022-11-01)

Effect of dopaminergic therapy on lacrimation in Parkinson's disease
door: A. A. Pilipovich, et al.
Gepubliceerd in: (2023-12-01)

Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update
door: E. Maruthi Prasad, et al.
Gepubliceerd in: (2021-07-01)

Application of immunoassay in the detection of amantadine residues
door: WANG Lin, et al.
Gepubliceerd in: (2023-06-01)

Amantadine and Rimantadine Analogues—Single-Crystal Analysis and Anti-Coronaviral Activity
door: Kalina Shishkova, et al.
Gepubliceerd in: (2023-09-01)

Use of amantadine in the evaluation of response to chemotherapy in lung cancer: a pilot study
door: Andrew W Maksymiuk, et al.
Gepubliceerd in: (2021-04-01)

Development of N,N-Dimethylglycine-Amantadine for Adjunctive Dopaminergic Application: Synthesis, Structure and Biological Activity
door: Radoslav Chayrov, et al.
Gepubliceerd in: (2022-08-01)

Amantadine in Absence Epilepsy
door: J Gordon Millichap
Gepubliceerd in: (1992-12-01)

Ribose-cysteine and levodopa abrogate Parkinsonism via the regulation of neurochemical and redox activities in alpha-synuclein transgenic Drosophila melanogaster models
door: Olumayowa K. Idowu, et al.
Gepubliceerd in: (2024-12-01)

Pharmaceutical-Induced Dyskinesia: A Case Study of Thoracotomy Treated with Amantadine
door: Mojtaba Mojtahedzadeh, et al.
Gepubliceerd in: (2025-02-01)

ATPase Thorase Deficiency Causes α-Synucleinopathy and Parkinson’s Disease-like Behavior
door: Fei Gao, et al.
Gepubliceerd in: (2022-09-01)

Rapid eye movement sleep behavior disorder: modern concept and Parkinson’s disease correlation
door: Diana M. Khasanova, et al.
Gepubliceerd in: (2024-07-01)

Vitamin B<sub>12</sub> deficiency and Parkinson’s disease
door: Z. A. Zalyalova, et al.
Gepubliceerd in: (2023-07-01)

Progress of deacetylase SIRTs in pathogenesis of Parkinson's disease
door: FANG Xue, SHI Jin, LI Haining, YANG Juan
Gepubliceerd in: (2024-11-01)

Erythrocytic α-Synuclein in Parkinson’s Disease and Progressive Supranuclear Palsy—A Pilot Study
door: Costanza Maria Cristiani, et al.
Gepubliceerd in: (2024-11-01)

The Neuroprotective Effects of Electroacupuncture on Parkinson's Disease and the Underlying Molecular Mechanisms
door: Qiuqin Han, et al.
Gepubliceerd in: (2024-01-01)

Investigation of <i>PRKN</i> Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
door: Ana Gabrielle Bispo, et al.
Gepubliceerd in: (2023-08-01)

Belly dancer syndrome improved by withdrawal of droxidopa and amantadine
door: Mihiro Kaga, et al.
Gepubliceerd in: (2023-04-01)

Antiglycoxidative properties of amantadine – a systematic review and comprehensive in vitro study
door: Miłosz Nesterowicz, et al.
Gepubliceerd in: (2023-12-01)

Parkinson’s disease and exosomes: from pathogenesis to diagnosis and treatment
door: A. Mišeikaitė, et al.
Gepubliceerd in: (2021-06-01)

Navigating the Neurobiology of Parkinson’s: The Impact and Potential of α-Synuclein
door: Erlandas Paulėkas, et al.
Gepubliceerd in: (2024-09-01)

The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance
door: Elisa Menozzi, et al.
Gepubliceerd in: (2021-01-01)

Emerging role of microglia in inter-cellular transmission of α-synuclein in Parkinson’s disease
door: Xiangbo Zhang, et al.
Gepubliceerd in: (2024-10-01)

Amantadine Inhibits SARS-CoV-2 In Vitro
door: Klaus Fink, et al.
Gepubliceerd in: (2021-03-01)

Evaluation of the Therapeutic Potential of Amantadine in a Vincristine-Induced Peripheral Neuropathy Model in Rats
door: Isabela Santana Albertazzi Drummond, et al.
Gepubliceerd in: (2024-06-01)

Comparison of LC-MS<sup>3</sup> and LC-MRM Methods for Quantifying Amantadine and Its Application in Therapeutic Amantadine Monitoring in Human Plasma
door: Qiang Sun, et al.
Gepubliceerd in: (2022-11-01)

Update on CSF Biomarkers in Parkinson’s Disease
door: Eun Hae Kwon, et al.
Gepubliceerd in: (2022-02-01)

Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease
door: Samuel Peña-Díaz, et al.
Gepubliceerd in: (2023-03-01)

Amantadine induced interface fluid formation after LASIK. A case report
door: Alexander Altman, et al.
Gepubliceerd in: (2023-12-01)

Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
door: Marek Krzystanek, et al.
Gepubliceerd in: (2023-06-01)

The Links between Parkinson’s Disease and Cancer
door: Maria Ejma, et al.
Gepubliceerd in: (2020-10-01)

A multicenter, randomized, double-blind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest
door: Patrick J. Coppler, et al.
Gepubliceerd in: (2024-06-01)

Use of amantadine in traumatic brain injury: an updated meta-analysis of randomized controlled trials
door: João Félix, et al.
Gepubliceerd in: (2025-01-01)

Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
door: Marek Krzystanek, et al.
Gepubliceerd in: (2020-10-01)

AMPK Signaling Pathway as a Potential Therapeutic Target for Parkinson’s Disease
door: Seyed Zanyar Athari, et al.
Gepubliceerd in: (2024-03-01)

Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson’s Disease
door: Chen-Chih Chung, et al.
Gepubliceerd in: (2021-05-01)

The risk of developing motor complications with Levodopa immediate versus dual release upon treatment initiation in Parkinson’s disease
door: Christian Ineichen, et al.
Gepubliceerd in: (2023-01-01)